Sheeba Cantanelli, MPAS, PA-C, on Pembrolizumab Plus Chemotherapy for Previously Untreated, Locally Recurrent, Inoperable or Metastatic Triple-Negative Breast Cancer

Sheeba Cantanelli, MPAS, PA-C, of UT Southwestern Simmons Cancer Center, discusses the final phase III results of KEYNOTE-355, which advanced practitioners need to be aware of. The study showed that pembrolizumab and chemotherapy improved overall and progression-free survival, compared with placebo and chemotherapy, for patients with previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (Abstract GS1-02).